EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

被引：0
|
作者：
Van der Heijde, D. [1 ]
Gensler, L. S. [2 ]
Deodhar, A. [3 ]
Baraliakos, X. [4 ]
Poddubnyy, D. [5 ]
Kivitz, A. [6 ]
Farmer, M. K. [7 ]
Baeten, D. [8 ]
Goldammer, N. [9 ]
Coarse, J. [7 ]
Oortgiesen, M. [7 ]
Dougados, M. [10 ,11 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Rheumazentrum Ruhrgebiet, Herne, Germany
[5] Charite Univ Med Berlin, German Rheumatism Res Ctr, Berlin, Germany
[6] Altoona Ctr Clin Res, Duncansville, PA USA
[7] UCB Pharma, Raleigh, NC USA
[8] UCB Pharma, Slough, Berks, England
[9] UCB Pharma, Monheim, Germany
[10] Univ Paris, Dept Rheumatol, Paris, France
[11] INSERM, PRES Sorbonne Paris Cite, Epidemiol Clin & Biostat U1153, Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.323
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0105
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [1] Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Ritchlin, Christopher T.
    Kavanaugh, Arthur
    Merola, Joseph F.
    Schett, Georg
    Scher, Jose U.
    Warren, Richard B.
    Gottlieb, Alice B.
    Assudani, Deepak
    Bedford-Rice, Kathy
    Coarse, Jason
    Ink, Barbara
    McInnes, Iain B.
    LANCET, 2020, 395 (10222): : 427 - 440
  • [2] Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
    van der Heijde, Desiree
    Gensler, Lianne S.
    Deodhar, Atul
    Baraliakos, Xenofon
    Poddubnyy, Denis
    Kivitz, Alan
    Farmer, Mary Katherine
    Baeten, Dominique
    Goldammer, Nadine
    Coarse, Jason
    Oortgiesen, Marga
    Dougados, Maxime
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (05) : 595 - 604
  • [3] XIMOPROFEN IN ANKYLOSING-SPONDYLITIS - A DOUBLE-BLIND PLACEBO-CONTROLLED DOSE-RANGING STUDY
    DOUGADOS, M
    NGUYEN, M
    CAPORAL, R
    LEGEAIS, J
    BOUXINSAUZET, A
    PELLEGRIGUEGNAULT, B
    GOMENI, C
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1994, 23 (05) : 243 - 248
  • [4] Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
    van der Heijde, Desiree
    Gensler, Lianne
    Deodhar, Atul
    Baraliakos, Xenofon
    Poddubnyy, Denis
    Kivitz, Alan
    Oortgiesen, Marga
    Baeten, Dominique
    Goldammer, Nadine
    Coarse, Jason
    Farmer, M. K.
    Dougados, Maxime
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [5] DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
    van der Heijde, Desiree
    Gensler, Lianne S.
    Deodhar, Atul
    Baraliakos, Xenofon
    Poddubnyy, Denis
    Farmer, Mary Katherine
    Baeten, Dominique
    Coarse, Jason
    Oortgiesen, Marga
    Dougados, Maxime
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 193 - 193
  • [6] DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS): 12-WEEK RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
    van der Heijde, D.
    Gensler, L. S.
    Deodhar, A.
    Baraliakos, X.
    Poddubnyy, D.
    Farmer, M. K.
    Baeten, D.
    Kumke, T.
    Oortgiesen, M.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 70 - 70
  • [7] TOFACITINIB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A PHASE 2, 16-WEEK, RANDOMISED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
    van der Heijde, D.
    Deodhar, A.
    Wei, J. C.
    Drescher, E.
    Fleishaker, D.
    Hendrikx, T.
    Li, D.
    Menon, S.
    Kanik, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 52 - 53
  • [8] Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis: A Randomised, Double-blind, Placebo-controlled Trial
    Harish, B., V
    Sahoo, Rasmi Ranjan
    Gochhait, Samanyoya
    Patro, Pradeepta Sekhar
    INDIAN JOURNAL OF RHEUMATOLOGY, 2025, 20 (01) : 27 - 34
  • [9] Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
    van der Heijde, Desiree
    Deodhar, Atul
    Wei, James C.
    Drescher, Edit
    Fleishaker, Dona
    Hendrikx, Thijs
    Li, David
    Menon, Sujatha
    Kanik, Keith S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1340 - 1347
  • [10] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Dubourg, Julie
    Ueki, Kohjiro
    Grouin, Jean-Marie
    Fouqueray, Pascale
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
12345